Zydus gets COFEPRIS nod to market Bhava to treat various cancers
Bhava, a Bevacizumab biosimilar and will be marketed in different strengths of 100 mg/4 ml and 400 mg/16 ml
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bevacizumab biosimilar
EMA approves Biocon’s new mAbs facility in India
EMA also renews GMP certifications for Biocon’s India and Malaysia sites